Parathyroid Adenoma - The Leading Cause of Primary Hyperparathyroidism: Case Report
DOI:
https://doi.org/10.12775/QS.2025.37.57426Keywords
Primary Hyperparathyroidism, parathyroid, Osteoporosis, vitamin D, parathormoneAbstract
Primary hyperparathyroidism is an endocrine disorder characterized by excessive secretion of parathyroid hormone (PTH) by the parathyroid glands, disproportionate to the physiological requirement for calcium concentration. This hypersecretion of PTH occurs independently of dysregulation in calcium-phosphate metabolism. The predominant etiology of primary hyperparathyroidism is the presence of a parathyroid adenoma. (7)
This case report presents a 68-year-old female patient with a history of osteoporosis, diagnosed in 2019 for osteoarticular pain and hypercalcemia. The suboptimal response to standard osteoporosis treatment was an indication to expand the diagnosis of calcium-phosphate disorders accompanying osteoporosis. Diagnostic evaluation confirmed primary hyperparathyroidism due to parathyroid adenoma and appropriate therapeutic measures were subsequently implemented.
This report highlights the nonspecific clinical presentation of the disease and the diagnostic difficulties associated with illness. A multidisciplinary approach to the patient is required due to the multifaceted nature of the disease.
References
1. Hedback GM & Oden AS. Cardiovascular disease, hypertension and renal function in primary hyperparathyroidism. Journal of Internal Medicine 2002 251 476–483. (doi:10.1046/j.1365-2796.2002.00984.x)
2. Nilsson IL, Yin L, Lundgren E, Rastad J & Ekbom A. Clinical presentation of primary hyperparathyroidism in Europe – nation-wide cohort analysis on mortality from nonmalignant causes. Journal of Bone and Mineral Research 2002 17 (Suppl 2) N68–N74.
3. The Great Endocrinology Interna vol. 1 pages 392-403 Waldemar Misiorowski Publisher: Medical Tribune Polska
4. Szczeklik’s Internal Medicines Andrzej Szczeklik, Piotr Gajewski
Publisher: Medycyna Praktyczna
5. Gallowitsch H.J., Mikosch P., Kresnik E. i wsp. Technetium 99m tetrofosmin parathyroid imaging. Results with double- -phase study and SPECT in primary and secondary hyperparathyroidism. Invest. Radiol. 1997; 32: 459–465.
6. Ryan JA, Lee FT:Maximizing outcomes while minimizing exploration in hyperparathyroidism using localization tests. ArchSurg2004;139:838–842
7. Garas G., Poulasouchidou M., Dimoulas A., Hytiroglou P., Kita M. et al.: Radiologicalconsiderations and surgical planning in the treatment of giant parathyroidadenomas. Ann R Coll Surg Engl., 2015; 97(4): e64–66.
8. Outpatient minimally invasive parathyroidectomy: A combination of sestamibi-SPECT localization, cervical block anesthesia, and intraoperative parathyroid hormone assay Herbert Chen, MD, Lori J. Sokoll, PhD, and Robert Udelsman, MD, FACS, Baltimore, Md
9. Operation for primaryhyperparathyroidism: the new versus the Old Order A rarandomised controlled trial of preoperative localization s.aarum1,J.nordenström1,e.reihnér1,J.Zedenius1,h.Jacobsson2,r.danielsson3,
m. Bäckdahl1,h.lindholm2,G.wallin1,B.hamberger1,l.-O. farnebo1
10. Miccoli P, Pinchera A, Cecchini G, Conte M, Bendinelli C, Vignali E et al. Minimally invasive, video-assisted parathyroid surgery for primary hyperparathyroidism. J Endocrinol Invest 1997; 20: 429–430.
11. 7 Henry JF, Defechereux T, Gramatica L, de Boissezon C. Minimally invasive videoscopic parathyroidectomy by lateral approach. Langenbecks Arch Surg 1999; 384: 298–301.
12. Alendronate in Primary Hyperparathyroidism: A Double-Blind, Randomized, Placebo-Controlled Trial ALIYA A. KHAN, JOHN P. BILEZIKIAN, ANNIE W. C. KUNG, MUSTAFA M. AHMED, SACHA J. DUBOIS, ANDREW Y. Y. HO, DEBRA SCHUSSHEIM, MISHAELA R. RUBIN, ATIF M. SHAIKH, SHONNI J. SILVERBERG, TIMOTHY I. STANDISH, ZAREEN SYED, AND ZEBA A. SYED
13. Cinacalcet Treatment of Primary Hyperparathyroidism: Biochemical and Bone Densitometric Outcomes in a Five-Year Study Munro Peacock, Michael A. Bolognese, Michael Borofsky, Simona Scumpia, Lulu Ren Sterling, Sunfa Cheng, and Dolores Shoback
14. Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial Julius Simoni Leere, Jesper Karmisholt, Maciej Robaczyk, Simon Lykkeboe, Aase Handberg, Emilie Steinkohl, Jens Brøndum Frøkjær, Peter Vestergaard
15. Role of Vitamin D Supplements in Prevention of Hungry Bone Syndrome after Successful Parathyroidectomy for Primary Hyperparathyroidism: A Prospective Study M. A. Salman1 A. Rabiee2, A. Salman2 T. E. Ftohy4, K. K.Maurice1, H. Balamoun1
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Martyna Zielnik, Julia Dubel, Szymon Kalinowski, Sabina Kadłubek, Patrycja Rembisz, Anna Czuba, Pola Knurowska, Klaudia Serafin, Aleksander Wrona, Aleksandra Słowikowska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 340
Number of citations: 0
